Establishment Labs (ESTA) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
7 Aug, 2026Executive summary
Q2 2026 revenue reached $67.5 million, up 31.7% year-over-year, with adjusted EBITDA of $3.7 million, marking a turnaround from a loss last year.
Revenue for the first half of 2026 was $127.4 million, up 37.5% year-over-year, driven by strong U.S. and international sales.
U.S. revenue surged 140.9% to $24.7 million in Q2, now 36.6% of total revenue, fueled by Motiva adoption and Minimally Invasive platform growth.
Gross margin improved to 70.6% in Q2 2026, up from 68.8% last year, driven by higher-margin markets and favorable product mix.
Cash and equivalents ended at $71.2 million as of June 30, 2026, up $16.5 million year-over-year.
Financial highlights
Gross profit for Q2 2026 was $47.7 million (70.6% margin), up from $35.3 million (68.8% margin) in Q2 2025.
Operating expenses for Q2 2026 totaled $52.0 million, including $2.2 million in one-time charges.
Net loss narrowed to $11.7 million in Q2 2026 from $16.6 million in Q2 2025; net loss for the first half of 2026 was $25.1 million.
Adjusted EBITDA improved by $12.2 million to $3.7 million from a loss of $8.5 million last year.
Interest expense increased to $7.0 million in Q2 2026 due to higher debt levels.
Outlook and guidance
Full-year revenue guidance raised to $269–$271 million, with U.S. as primary growth driver and OUS business stable.
Management expects strong growth in the second half of 2026 and into 2027, with a focus on achieving free cash flow positivity.
Expect to be free cash flow positive in H2 2026 and for full-year 2027.
Anticipate 25% revenue growth in 2027, with Recon not expected to contribute materially until then.
Available cash and cash from operations are expected to satisfy liquidity requirements for at least the next 12 months.
Latest events from Establishment Labs
- All proposals passed with majority approval and no shareholder questions were raised.ESTA
AGM 2026 - Q1 revenue up 45% year-over-year, gross margin at 70.7%, and 2026 guidance raised.ESTA
Q1 2026 - Director compensation figures were corrected, and additional equity awards disclosed for consulting roles.ESTA
Proxy filing - Virtual meeting to elect directors, approve pay, and ratify auditor, with strong governance focus.ESTA
Proxy filing - Vote on directors, executive pay, and auditor ratification at the May 2026 annual meeting.ESTA
Proxy filing - Rapid U.S. growth, premium pricing, and innovation set the stage for market dominance and expansion.ESTA
TD Cowen 46th Annual Health Care Conference - Q4 revenue up 45%, gross margin at 70.5%, and 2026 revenue growth guided above 25%.ESTA
Q4 2025 - Q2 revenue rose 18.7% sequentially; FDA approval for Motiva Implants expected soon.ESTA
Q2 2024 - 2025 guidance targets $205–$210M revenue, EBITDA positive, and rapid US-driven growth.ESTA
Investor Day 2025